Please provide your email address to receive an email when new articles are posted on . The etanercept biosimilar, LBEC0101, demonstrated equivalent clinical efficacy and comparable safety profile to ...
Eight months after bowing to FDA pressure to pull the original spot, Amgen has launched a revamped television ad for Enbrel (etanercept) that it says better explains the product’s psoriasis indication ...
THOUSAND OAKS, Calif., and RADNOR, Penn., – Results from a study of ENBREL® (etanercept), the only fully human TNF receptor, were presented demonstrating significant inhibition in the progression of ...
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., JUNE 19, 2003 – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today ...
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world. The Food and Drug ...
An appeals court ruling means biosimilar competition won't affect U.S. Enbrel sales for a long time. Enbrel is a tumor necrosis factor (TNF) inhibitor that earned its first FDA approval all the way ...
Never fear, makers of anti-TNF giants: Those pesky biosimilars? They won’t be halting revenue growth anytime soon, Leerink Partners analysts predict. Taking into account current trends in prescription ...
WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...
EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that there has been a slight increase in ...
On Monday, May 17 th, the U.S. Supreme Court decided not to take up Sandoz’s petition for the Court to review previous lower court decisions on the launch of its biosimilar product. This included a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results